XCELL AMNIO MATRIX

What this record means

The record shows that “XCELL AMNIO MATRIX” is a live, registered mark on the Principal Register owned by Precise Bioscience Corporation. It protects the use of a biological amniotic membrane allograft for post‑surgery wound care, first used in commerce on December 1, 2019. A similar name would raise the closest concern in the same pharmaceutical field, especially for products or services involving amniotic membrane grafts. This registration does not give the owner control over every use of the words “XCELL,” “AMNIO,” or “MATRIX” in unrelated contexts. The prosecution history indicates a final refusal was issued on November 9, 2020, followed by a successful appeal and registration on March 9, 2021. The most recent event is the 2026 abandonment request under Section 7, which has not yet been acted upon. No oppositions or cancellations appear in the supplied history, so there is no visible enforcement activity. For someone considering a similar name, the record suggests a meaningful risk of conflict in the amniotic membrane wound‑care market.